Hosted on Acast. See acast.com/privacy for more information.
Take our post-test to claim CME credits.
To listen to our full-length podcast, click here.
Hosted on Acast. See acast.com/privacy for more information.
Take our post-test to claim CME credits.
To listen to our full-length podcast, click here.
Hosted on Acast. See acast.com/privacy for more information.
Take our post-test to claim CME credits.
To listen to our full-length podcast, click here.
Hosted on Acast. See acast.com/privacy for more information.
Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That’s the focus of this Special HBV…
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Why has finding a cure for hepatitis B infection been so challenging? What is it about this virus and its life cycle …
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hepatitis C has become “curable” for >90% of those infected. But while universal HCV elimination is medically possib…
Take our post-test to claim CME credits.
To read a companion newsletter click here.
The extrahepatic manifestations of chronic HCV can affect many different organ systems. In this eViralHepatitis Revi…
In this issue, Drs. Jordan Feld and Lisette Krassenburg from the Toronto Centre for Liver Disease at the University of Toronto apply the information in their recent newsletter issue to clinical pract…
In this podcast follow-up to their recent eViralHepatitis Review newsletter issue (Vol. 6, No. 5), Dr. Mandana Khalili and Dr. Michele Tana from the University of California, San Francisco discuss ho…
People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will cont…
Among the many extrahepatic complications of hepatitis C infection that contribute to increased morbidity and mortality are CV (cryoglobulinemic vasculitis) and CKD chronic kidney disease).
In this is…
Volume 5, Issue 10.
In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C.
Take our post-test to claim CME credits:
Physician post-tes…
Volume 5, Issue 8.
In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 …
Volume 5, Issue 6.
This podcast, Andrew H. Talal, MD, MPH and Richard Blondell, MD from the University at Buffalo discuss expanding HCV screening in persons with substance abuse disorders.
Take our pos…
Volume 5, Issue 4.
In this podcast Daryl T. Y. Lau, MD, MSc, MPH from Harvard Medical School discussed how to evaluate and mange patients who do not meet treatment criteria, the management of chronic …
Volume 5, Issue 2.
Our guests authors are Mindie Nguyen, MD, MAS, from Associate Professor of Medicine at Stanford University, and Dr. Iris Liou, MD of the University of Washington.
Take our post-test …
Volume 4, Issue 14.
Drs Jordan Feld, MD, MPH and Joel Emery, HBSc, MD cover the important topic of Extrahepatic Manifestations of Hepatitis C: Screening and Management in the format of case-study scen…
Volume 4, Issue 12.
Our guest author is Chloe Thio, MD, Professor of Medicine, Divison of Infectious Diseases at the Johns Hopkins University School of Medicine.
Take our post-test to claim CME credits…
Volume 4, Issue 10.
Drs Kenneth Sherman, MD, PhD and Nadeem Anwar, MD cover the important topic of New Approaches to the Diagnosis and Management of Chronic HBV Infection in the format of case-study s…